152 related articles for article (PubMed ID: 28202921)
1. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies.
Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX
Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921
[TBL] [Abstract][Full Text] [Related]
2. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Weir GM; Hrytsenko O; Quinton T; Berinstein NL; Stanford MM; Mansour M
J Immunother Cancer; 2016; 4():68. PubMed ID: 27777777
[TBL] [Abstract][Full Text] [Related]
3. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
4. Preferential Expression of Programmed Death Ligand 1 Protein in Tumor-Associated Macrophages and Its Potential Role in Immunotherapy for Hepatocellular Carcinoma.
Park DJ; Sung PS; Lee GW; Cho S; Kim SM; Kang BY; Hur W; Yang H; Lee SK; Lee SH; Jung ES; Seo CH; Ahn J; Choi HJ; You YK; Jang JW; Bae SH; Choi JY; Yoon SK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946835
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment.
Umezu D; Okada N; Sakoda Y; Adachi K; Ojima T; Yamaue H; Eto M; Tamada K
Cancer Immunol Immunother; 2019 Feb; 68(2):201-211. PubMed ID: 30357491
[TBL] [Abstract][Full Text] [Related]
6. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.
Herbst RS; Soria JC; Kowanetz M; Fine GD; Hamid O; Gordon MS; Sosman JA; McDermott DF; Powderly JD; Gettinger SN; Kohrt HE; Horn L; Lawrence DP; Rost S; Leabman M; Xiao Y; Mokatrin A; Koeppen H; Hegde PS; Mellman I; Chen DS; Hodi FS
Nature; 2014 Nov; 515(7528):563-7. PubMed ID: 25428504
[TBL] [Abstract][Full Text] [Related]
7. Targeting PD-L1 in solid cancer with myeloid cells expressing a CAR-like immune receptor.
Myers Chen K; Grun D; Gautier B; Venkatesha S; Maddox M; Zhang AH; Andersen P
Front Immunol; 2024; 15():1380065. PubMed ID: 38726005
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment.
Ren Z; Yang K; Zhu L; Yin D; Zhou Y
Int Immunopharmacol; 2024 May; 132():111934. PubMed ID: 38574701
[TBL] [Abstract][Full Text] [Related]
9. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.
Mariathasan S; Turley SJ; Nickles D; Castiglioni A; Yuen K; Wang Y; Kadel EE; Koeppen H; Astarita JL; Cubas R; Jhunjhunwala S; Banchereau R; Yang Y; Guan Y; Chalouni C; Ziai J; Şenbabaoğlu Y; Santoro S; Sheinson D; Hung J; Giltnane JM; Pierce AA; Mesh K; Lianoglou S; Riegler J; Carano RAD; Eriksson P; Höglund M; Somarriba L; Halligan DL; van der Heijden MS; Loriot Y; Rosenberg JE; Fong L; Mellman I; Chen DS; Green M; Derleth C; Fine GD; Hegde PS; Bourgon R; Powles T
Nature; 2018 Feb; 554(7693):544-548. PubMed ID: 29443960
[TBL] [Abstract][Full Text] [Related]
10. Human PD-L1 overexpression decreases xenogeneic human T-cell immune responses towards porcine kidneys.
Schmalkuche K; Rother T; Besli S; Schwinzer R; Blasczyk R; Petersen B; Figueiredo C
Front Immunol; 2024; 15():1279050. PubMed ID: 38352884
[TBL] [Abstract][Full Text] [Related]
11. Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model.
Mony JT; Zhang L; Ma T; Grabosch S; Tirodkar TS; Brozick J; Tseng G; Elishaev E; Edwards RP; Huang X; Vlad AM
Cancer Immunol Immunother; 2015 Sep; 64(9):1095-108. PubMed ID: 25998800
[TBL] [Abstract][Full Text] [Related]
12. GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy.
Kim HM; Kim KJ; Lee K; Yoon MJ; Choih J; Hong TJ; Cho EJ; Jung HJ; Kim J; Park JS; Na HY; Heo YS; Park CG; Park H; Han S; Bae D
BMC Immunol; 2024 May; 25(1):29. PubMed ID: 38730320
[TBL] [Abstract][Full Text] [Related]
13. Multi-Parameter Quantitative Imaging of Tumor Microenvironments Reveals Perivascular Immune Niches Associated With Anti-Tumor Immunity.
Stoltzfus CR; Sivakumar R; Kunz L; Olin Pope BE; Menietti E; Speziale D; Adelfio R; Bacac M; Colombetti S; Perro M; Gerner MY
Front Immunol; 2021; 12():726492. PubMed ID: 34421928
[TBL] [Abstract][Full Text] [Related]
14. Engineering of a novel subnanomolar affinity fibronectin III domain binder targeting human programmed death-ligand 1.
Ramakrishnan S; Natarajan A; Chan CT; Panesar PS; Gambhir SS
Protein Eng Des Sel; 2019 Dec; 32(5):231-240. PubMed ID: 31612217
[TBL] [Abstract][Full Text] [Related]
15. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer.
Komura N; Mabuchi S; Shimura K; Yokoi E; Kozasa K; Kuroda H; Takahashi R; Sasano T; Kawano M; Matsumoto Y; Kodama M; Hashimoto K; Sawada K; Kimura T
Cancer Immunol Immunother; 2020 Dec; 69(12):2477-2499. PubMed ID: 32561967
[TBL] [Abstract][Full Text] [Related]
16. B7H4 expression in tumor cells impairs CD8 T cell responses and tumor immunity.
Zhou L; Ruan M; Liu Y; Zhu Y; Fu D; Wu K; Zhang Q
Cancer Immunol Immunother; 2020 Feb; 69(2):163-174. PubMed ID: 31848656
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity.
Erkes DA; Xu G; Daskalakis C; Zurbach KA; Wilski NA; Moghbeli T; Hill AB; Snyder CM
Mol Ther; 2016 Aug; 24(8):1444-55. PubMed ID: 27434584
[TBL] [Abstract][Full Text] [Related]
18. Egr2-independent, Klf1-mediated induction of PD-L1 in CD4
Teruya S; Okamura T; Komai T; Inoue M; Iwasaki Y; Sumitomo S; Shoda H; Yamamoto K; Fujio K
Sci Rep; 2018 May; 8(1):7021. PubMed ID: 29728568
[TBL] [Abstract][Full Text] [Related]
19. Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T
Guan X; Hu R; Choi Y; Srivats S; Nabet BY; Silva J; McGinnis L; Hendricks R; Nutsch K; Banta KL; Duong E; Dunkle A; Chang PS; Han CJ; Mittman S; Molden N; Daggumati P; Connolly W; Johnson M; Abreu DR; Cho BC; Italiano A; Gil-Bazo I; Felip E; Mellman I; Mariathasan S; Shames DS; Meng R; Chiang EY; Johnston RJ; Patil NS
Nature; 2024 Mar; 627(8004):646-655. PubMed ID: 38418879
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 and Emerging Biomarkers in Immune Checkpoint Blockade Therapy.
Cottrell TR; Taube JM
Cancer J; 2018; 24(1):41-46. PubMed ID: 29360727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
